Brain Aneurysm, Intracranial Hemorrhages, Stroke
Conditions
Brief summary
In this project the investigators study the safety and efficacy of the pipeline embolization device with vantage technology in treatment of unruptured brain aneurysms
Interventions
DEVICEPipeline Embolization Device with Vantage Technology
Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
Sponsors
King's College Hospital NHS Trust
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients treated with Pipeline Embolization Device with Vantage Technology (PEDV) * MRA and/or DSA (or tomographic angiography) available for follow up
Exclusion criteria
* Insufficient background data available e.g., to determine size of aneurysm and pipeline device * PEDV used for causes other than aneurysms, e.g., fistulas and dissection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate 30-day morbidity rates | Done at 30 days post procedural | We will evaluate short term clinical outcome in the form of morbidity rates 30 days after the procedure |
| Evaluate 30-day mortality rates | Done at 30 days post procedural | We will evaluate short term clinical outcome in the form of mortality rates 30 days after the procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate 1-year morbidity rates | Done at >30days up to 1 year post procedural | We will evaluate long term clinical outcome in the form of morbidity rates \>30days up to 1 year after the procedure |
| Evaluate 1-year mortality rates | Done at >30days up to 1 year post procedural | We will evaluate long term clinical outcome in the form of mortality rates \>30days up to 1 year after the procedure |
Countries
United Kingdom
Outcome results
None listed